Global R&D Pipeline
My Favorite
Hot Targets:
TGF-β1
Back
Total number of drugs
100
Phase II and later clinical stages
9%
Involving companies
130
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xihuang pill(Beijing University of Chinese Medicine) | Xihuang pill(Beijing University of Chinese Medicine) | Herbal medicine | Neoplasms Skin and Musculoskeletal Diseases | AXL modulators ERK modulators RHOA modulators ROCK modulators TGF-β1 modulators | Beijing University of Traditional Chinese Medicine | Beijing University of Traditional Chinese Medicine | Preclinical | Preclinical | - | - | - | - | - | - | - | - | Xihuang pill(Beijing University of Chinese Medicine) | - | - | detail > | |
| AVA-027 | AVA-027 | Antibody fusion proteins | Neoplasms | PDL1 inhibitors TGF-β1 inhibitors | Avacta Group Plc | Avacta Group Plc | Preclinical | - | - | - | - | - | - | - | - | - | AVA-027 | - | - | detail > | |
| ABP2 | ABP2 | Chemical drugs | Respiratory Diseases | TGF-β1 inhibitors Intestinal microbiota regulator | Medical School of Pingdingshan University Henan University of Traditional Chinese Medicine | Medical School of Pingdingshan University Henan University of Traditional Chinese Medicine | Preclinical | - | - | - | - | - | - | - | - | - | ABP2 | - | - | detail > | |
| LY-364937 | LY-364937 | Small molecule drug | Neoplasms Respiratory Diseases | TGF-β1 inhibitors | Eli Lilly & Co. | Eli Lilly & Co. | Preclinical | - | - | - | - | - | - | - | - | - | LY-364937 | - | - | detail > | |
| BMS-986260 | BMS-986260 | Small molecule drug | Neoplasms Digestive System Disorders | TGF-β1 inhibitors | Bristol Myers Squibb Co. | Rigel Pharmaceuticals, Inc. Bristol Myers Squibb Co. Bristol-Myers Squibb India Pvt Ltd. | Preclinical | - | - | - | - | - | - | - | - | - | BMS-986260 | - | - | detail > | |
| Anti FAP antibody -TGFβRII fusion protein (Leads Biolabs) | Anti FAP antibody -TGFβRII fusion protein (Leads Biolabs) | Antibody fusion proteins | Other Diseases | FAP antagonists TGF-β1 inhibitors TGF-β2 inhibitors TGF-β3 inhibitors | Nanjing Leads Biolabs Co., Ltd. | Nanjing Leads Biolabs Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | Anti FAP antibody -TGFβRII fusion protein (Leads Biolabs) | - | - | detail > | |
| SB-525334 | SB-525334 | Small molecule drug | Neoplasms Endocrinology and Metabolic Disease Urogenital Diseases | ALK5 inhibitors TGF-β1 inhibitors | GlaxoSmithKline, Inc. | Ewha Womans University GSK Plc GlaxoSmithKline LLC | Preclinical | - | - | - | - | - | - | - | - | - | SB-525334 | - | - | detail > | |
| Targeting TGF-B1 ASO(Isarna Therapeutics) | Targeting TGF-B1 ASO(Isarna Therapeutics) | ASO | Neoplasms | TGF-β1 inhibitors | Isarna Therapeutics, Inc. | Isarna Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | Targeting TGF-B1 ASO(Isarna Therapeutics) | - | - | detail > | |
| BTI-615 | BTI-615 | Synthetic peptide | Respiratory Diseases | TGF-β1 inhibitors | Brilliant Pharmaceutical Co. Ltd. | Brilliant Pharmaceutical Co. Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | BTI-615 | - | - | detail > | |
| RJB-02 | RJB-02 | Gene therapy | Skin and Musculoskeletal Diseases | TGF-β1 modulators α-Klotho modulators | Rejuvenate Bio, Inc. | Rejuvenate Bio, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | RJB-02 | - | - | detail > |
Total 100 data
1
2
3
4
5
6
...
9
10
